Prudential Financial Inc. Purchases 12,132 Shares of Insmed Incorporated (NASDAQ:INSM)

Prudential Financial Inc. lifted its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 9.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 146,722 shares of the biopharmaceutical company's stock after buying an additional 12,132 shares during the quarter. Prudential Financial Inc. owned about 0.08% of Insmed worth $10,130,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Abel Hall LLC raised its stake in shares of Insmed by 4.7% in the fourth quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company's stock worth $230,000 after acquiring an additional 151 shares during the last quarter. Steward Partners Investment Advisory LLC raised its position in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares during the last quarter. M&T Bank Corp lifted its holdings in Insmed by 5.6% during the 4th quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock worth $217,000 after buying an additional 166 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Insmed by 5.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock valued at $244,000 after buying an additional 183 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Insmed by 3.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company's stock valued at $446,000 after buying an additional 186 shares during the period.

Remove Ads

Insmed Stock Performance

INSM stock traded up $0.02 during trading hours on Wednesday, reaching $72.02. The stock had a trading volume of 737,674 shares, compared to its average volume of 2,228,772. The stock has a market capitalization of $13.04 billion, a PE ratio of -12.91 and a beta of 1.28. The stock has a 50-day simple moving average of $78.16 and a 200 day simple moving average of $74.00. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The company had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In other news, CEO William Lewis sold 18,750 shares of the business's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the sale, the chief executive officer now owns 384,960 shares of the company's stock, valued at approximately $26,885,606.40. The trade was a 4.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Martina M.D. Flammer sold 3,344 shares of the firm's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the transaction, the insider now directly owns 102,766 shares in the company, valued at approximately $6,773,307.06. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 550,957 shares of company stock worth $42,992,528 in the last ninety days. 4.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

INSM has been the subject of a number of recent research reports. Guggenheim restated a "buy" rating and set a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. Truist Financial upped their target price on shares of Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Stifel Nicolaus lowered their price target on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. Morgan Stanley increased their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Finally, Bank of America raised their price target on Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $94.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.